European Pharmaceutical Contractor (EPC) is designed to fill a unique position in pharmaceutical publishing. Providing a dedicated platform of communication and information for the international pharmaceutical contract market, it consists of a series of articles and case studies written by eminent figures in contractor groups and traditional multinational pharmaceutical companies.
Each quarterly edition examines areas of importance – both economic and technical – to contract research organisations, contract manufacturers, regulatory controllers, consultants and analysts. This enables regulatory bodies to link directly with policy-makers both in major contractor groups and pharmaceutical companies, and thereby convey regulatory information directly from the governing bodies, but also ensure debate between the policy-makers and consultancy groups.
Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.
Edited by
Dr Graham Hughes,
Consultant in
Pharmaceutical
Development
Published quarterly in
March, June,
September and December
Industry Events
Clinical Trial Supply New England
10-11 March 2015, Boston, USA
We are delighted to announce the Clinical Trial Supply New Englandconference will be taking place in Boston
on the 10th and 11th March 2015.
Building on the growing success of this conference, the 3rd annual event will once again provide a unique platform for discussion and
debate into the biggest challenges currently facing the clinical supply chain. More info >>
How to Achieve High Speed High Resolution Glycan Mapping for MAb Characterization
To help researchers overcome the challenges associated with glycan analysis, Agilent has introduced its AdvanceBio Glycan Mapping columns
which have been engineered and manufactured to deliver rapid,
reproducible, high-resolution glycan identification to increase
throughput without sacrificing the quality of data. More info >>
Clinical Trials in Russia Orange Paper: 2nd Quarter 2014
Synergy Research Group
The Ministry of Health of Russian Federation approved 194 new clinical
trials of all types including local and bioequivalence studies during
the 2nd Quarter of 2014 (3% less than at the same period of the last
year).
The main contribution to the total number of studies was
made by multinational multi-center clinical trials (MMCT) and the number
of these studies stayed the same as in Q2 2013 – 81 studies. The number
of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to
59 in Q2 2014, a 22% decrease from last year’s figure. The number of
local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical
trials in Q2 2014. More info >>
